Intraocular pressure increase (IOPi) after intravitreal injections of vascular endothelial growth factor inhibitors (VEGFis) might be different between different VEGFi (bevacizumab, aflibercept, ranibizumab). The purpose of this study was to evaluate the risk of IOPi among new users of bevacizumab, ranibizumab, and aflibercept in non-diabetic patients in Tuscany, Italy.
Spini, A., Giometto, S., Donnini, S., Posarelli, M., Dotta, F., Ziche, M., et al. (2023). Risk of intraocular pressure increase with intravitreal injections of Vascular Endothelial Growth Factor Inhibitors: a cohort study. AMERICAN JOURNAL OF OPHTHALMOLOGY, 248, 45-50 [10.1016/j.ajo.2022.11.015].
Risk of intraocular pressure increase with intravitreal injections of Vascular Endothelial Growth Factor Inhibitors: a cohort study
Spini, AndreaInvestigation
;Donnini, SandraWriting – Original Draft Preparation
;Dotta, FrancescoWriting – Review & Editing
;Tosi, Gian MarcoWriting – Review & Editing
;
2023-01-01
Abstract
Intraocular pressure increase (IOPi) after intravitreal injections of vascular endothelial growth factor inhibitors (VEGFis) might be different between different VEGFi (bevacizumab, aflibercept, ranibizumab). The purpose of this study was to evaluate the risk of IOPi among new users of bevacizumab, ranibizumab, and aflibercept in non-diabetic patients in Tuscany, Italy.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0002939422004408-main.pdf
accesso aperto
Descrizione: Accepted Version
Tipologia:
Post-print
Licenza:
Creative commons
Dimensione
550.84 kB
Formato
Adobe PDF
|
550.84 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S0002939422004408-main.pdf
non disponibili
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
282.26 kB
Formato
Adobe PDF
|
282.26 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1222775